title: Medullary thyroid carcinoma (MTC)--clinical and molecular aspects on the basis of own experience.
abstract: In our clinic 19615 patients were operated over 25 years on for goiter. Malignant thyroid neoplasms were found in 1049 (5.3%) patients including 875 (83.4%) women and 174 (16.6%) men. Sixty two adult patients (42 women and 20 men were operated on for medullary thyroid carcinoma (MTC). Thyroid cancer was diagnosed in this group pre or intraoperatively in 44 (71%) patients and postoperatively, on histologic examination, in 18 (29%) patients. These patients were reoperated. Radical operations (total thyroidectomy with regional lymph node removal) were conducted in 43 (69.3%) patients and palliative ones in 19 (30.7%) patients. After MTC surgery, MEN 2A (MTC and an adrenal tumor) were diagnosed by means of imaging techniques (USG, CT) in 6 (9.7%) patients. All adrenal tumors were unilateral. Five of these patients were operated, and pheochromocytoma was confirmed by histopathologic examination. Two years after the MTC operation, 1 women was lost to follow-up. After a year, she was admitted to hospital for severe hypertension and died of cerebral hemorrhagia. Pheochromocytoma was revealed by autopsy. All patients were treated complementarily after the MTC operation. Different combinations of teleradiotherapy, chemotherapy and substitutive doses of levothyroxine were used. Ten (23.2%) of 43 patients operated radically were reoperated 1-3 years after the first operation due to loco-regional tumor recurrence. Radical reoperations were performed in 4 patients, and palliative ones in 6. Over a 0.5-23-year follow-up period, 26 (41.9%) patients died, including 20 of cancer, and 6 of other reasons. Four out of 36 living patients have clinical or biochemical symptoms of neoplastic disease. The follow-up period of MEN 2 patients operated on ranged from 1 to 6 years. Up to now, no tumor in the second adrenal gland has been diagnosed in any of these patients. Genetic (molecular) tests performed in 31 out of 36 living patients revealed mutations of RET gene in 4 (12.9%).
authors.affiliation: Clinic of Endocrinological and General Surgery, Medical Unitversity of Lodz, Poland.
authors.forename: L
authors.initials: L
authors.lastname: Pomorski
authors.forename: J
authors.initials: J
authors.lastname: Bartkowiak
authors.forename: H
authors.initials: H
authors.lastname: Pisarek
authors.forename: M
authors.initials: M
authors.lastname: Bartos
authors.forename: J
authors.initials: J
authors.lastname: Narebski
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000175:diagnosis / Q000453:epidemiology; D000328:Adult; D018276:Carcinoma, Medullary / Q000401:mortality / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006042:Goiter / Q000150:complications / Q000601:surgery*; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D018813:Multiple Endocrine Neoplasia Type 2a / Q000175:diagnosis / Q000453:epidemiology; D016609:Neoplasms, Second Primary / Q000175:diagnosis / Q000453:epidemiology; D010673:Pheochromocytoma / Q000175:diagnosis / Q000453:epidemiology; D012086:Reoperation; D012189:Retrospective Studies; D016019:Survival Analysis; D013964:Thyroid Neoplasms / Q000401:mortality / Q000601:surgery*; D013965:Thyroidectomy